Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Outlook Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Lawrence A. Kenyon, will engage in a fireside chat at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will include opportunities for virtual one-on-one meetings with investors. Outlook Therapeutics is focused on developing ONS-5010/LYTENAVA (bevacizumab-vikg), the first FDA-approved ophthalmic formulation for retinal indications including wet AMD, DME, and BRVO. The webcast of the chat will be available on demand starting March 9, 2021.

MONMOUTH JUNCTION, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website here.

A video webcast of the fireside chat will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the conference and will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

About Outlook Therapeutics, Inc.        

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit www.outlooktherapeutics.com. 

CONTACTS:

Media Inquiries:
Harriet Ullman
Assistant Vice President
LaVoieHealthScience
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com 

FAQ

What is the purpose of Outlook Therapeutics' participation in the H.C. Wainwright Conference?

Outlook Therapeutics will engage in discussions about its developments and future plans, particularly concerning its lead product ONS-5010.

When will the fireside chat with Lawrence A. Kenyon take place?

The fireside chat is scheduled for March 9-10, 2021.

How can investors watch the webcast of the fireside chat?

The webcast will be available on demand starting March 9, 2021, at 7:00 AM ET on the Outlook Therapeutics website.

What is ONS-5010/LYTENAVA and its significance?

ONS-5010/LYTENAVA is a potential FDA-approved ophthalmic formulation aimed at treating retinal diseases, including wet AMD, DME, and BRVO.

What regulatory pathway will Outlook Therapeutics use for ONS-5010 approval?

Outlook Therapeutics plans to file ONS-5010 with the U.S. FDA under the BLA regulatory pathway.